전이성 유방암의 호르몬 치료 = Hormone Therapy for Metastatic Breast Cancer

다국어 초록 (Multilingual Abstract)

The treatment of metastatic breast cancer depends on the patient`s condition, site of metastasis, and molecular subtype of cancer. Hormone receptor-positive patients, which account for 60-70% of all breast cancer patients, have the advantage of having an effective, less-toxic, hormone therapy treatment. Hormone therapy should be used actively because it is very useful in terms of the patient`s quality of life, by increasing the response rate and delaying the progression of cancer. Recently, studies have examined the mechanism of resistance to hormone therapy. We need to combine various target therapies to overcome resistance. The development of therapeutic agents based on molecular biological characteristics should help to improve the survival of patients with metastatic breast cancer. (Korean J Med 2017;92:251-258)

참고문헌 (Reference)

1 Prowell TM, "What is the role of ovarian ablation in the management of primary and metastatic breast cancer today?" 9 : 507-517, 2004

2 Powles TJ, "Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial" 99 : 283-290, 2007

3 Kaufman B, "Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor2-positive, hormone receptor- positive metastatic breast cancer: results from the randomized phase III TAnDEM study" 27 : 5529-5537, 2009

4 Osborne CK, "The value of estrogen and progesterone receptors in the treatment of breast cancer" 46 (46): 2884-2888, 1980

5 Finn RS, "The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study" 16 : 25-35, 2015

6 Fisher B, "Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1study" 97 : 1652-1662, 2005

7 Mauri D, "Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis" 98 : 1285-1291, 2006

8 Mouridsen H, "Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group" 19 : 2596-2606, 2001

9 Wakeling AE, "Similarities and distinctions in the mode of action of different classes of antioestrogens" 7 : 17-28, 2000

10 Di Leo A, "Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer" 28 : 4594-4600, 2010

11 Wolff AC, "Randomized phase III placebo controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer" 31 : 195-202, 2013

12 Bachelot T, "Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study" 30 : 2718-2724, 2012

13 Buzdar A, "Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate" 19 : 3357-3366, 2001

14 Martín M, "Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study" 33 : 1045-1052, 2015

15 Paridaens RJ, "Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group" 26 : 4883-4890, 2008

16 Cristofanilli M, "Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer" 16 : 1904-1914, 2010

17 Carlson RW, "Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women" 28 : 3917-3921, 2010

18 Park IH, "Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy" 28 : 2705-2711, 2010

19 Goetz MP, "Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes" 23 : 9312-9318, 2005

20 Ellis M, "Overcoming endocrine therapy resistance by signal transduction inhibition" 9 (9): 20-26, 2004

21 Beatson GT, "On the treatment of inoperable carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases" 148 : 162-165, 1896

22 National Comprehensive Cancer Network, "NCCN Clinical Practice Guideline in Oncology (NCCN Guideline®) Breast Cancer. 2017 version" Nat ional Comprehensive Cancer Network

23 Taylor CW, "Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study" 16 : 994-999, 1998

24 Shou J, "Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer" 96 : 926-935, 2004

25 Kuukasjärvi T, "Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy" 14 : 2584-2589, 1996

26 Cardoso F, "Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up" 21 (21): v15-v19, 2010

27 Johnston S, "Lapatinib Combined withletrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer" 27 : 5538-5546, 2009

28 Goel S, "LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women" (4) : CD004562-, 2009

29 Mouridsen HT, "Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women" 22 : 1609-1621, 2006

30 Howell A, "Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma:a prospectively planned combined survival analysis of two multicenter trials" 104 : 236-239, 2005

31 Cristofanilli M, "Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial" 17 : 425-439, 2016

32 Robertson JF, "Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study" 136 : 503-511, 2012

33 Bergh J, "FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer" 30 : 1919-1925, 2012

34 Baselga J, "Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer" 366 : 520-529, 2012

35 Lumachi F, "Endocrine therapy of breast cancer" 18 : 513-522, 2011

36 Chia S, "Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT" 26 : 1664-1670, 2008

37 Lavinsky RM, "Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes" 95 : 2920-2925, 1998

38 Howell A, "Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial" 22 : 1605-1613, 2004

39 Klijn JG, "Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH)agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials" 19 : 343-353, 2001

40 Mehta RS, "Combination anastrozole and fulvestrant in metastatic breast cancer" 367 : 435-444, 2012

41 Smith CL, "Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen" 11 : 657-666, 1997

42 Lim HS, "Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer" 25 : 3837-3845, 2007

43 오창모, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2013" 대한암학회 48 (48): 436-450, 2016

44 Smith IE, "Aromatase inhibitors in breast cancer" 348 : 2431-2442, 2003

45 Bonneterre J, "Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study" 18 : 3748-3757, 2000

46 Santen RJ, "Adaptive hypersensitivity to estrogen: mechanism for sequential responses to hormonal therapy in breast cancer" 10 (10): 337S-345S, 2004

47 Robertson JF, "Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study" 27 : 4530-4535, 2009

48 Smith IE, "A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer" 25 : 3816-3822, 2007

49 Addo S, "A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers" 87 : 1354-1359, 2002